Justin Gregg, MD, on the Use of the Mediterranean Diet in Men With Localized Prostate Cancer

News
Video

The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.

The Mediterranean diet was revealed to be associated with a lower risk of Gleason Grade group progression among men with localized prostate cancer on active surveillance, according to a study (NCT00490763) published in Cancer.

These findings are consistent with previous reports of the Mediterranean diet, resulting in reductions in cancer morbidity and mortality. However, follow-up in larger studies of men enrolled on active surveillance are still necessary to verify patient- and cancer-specific effects of adherence to the Mediterranean diet in men with early-stage prostate cancer.

In an interview with CancerNetwork®, Justin Gregg, MD, assistant professor of Urology at The University of Texas MD Anderson Cancer Center as well as lead author of the study, discussed these findings and what led he and his colleagues to conduct this research.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences channels.

Reference:

Gregg JR, Zhang X, Chapin BF, et al. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. Published online January 7, 2020. doi:10.1002/cncr.33182

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content